EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
17 juil. 2023 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., July 17, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve...
EyePoint Pharmaceuticals Announces Chief Executive Officer Transition
10 juil. 2023 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
– Jay S. Duker, M.D., Previously President and Chief Operating Officer, Appointed President and Chief Executive Officer – – Nancy S. Lurker Transitions to Executive Vice Chair of the Board of...
EyePoint Pharmaceuticals Completes Enrollment in Phase 2 PAVIA Clinical Trial of EYP-1901 in Non-Proliferative Diabetic Retinopathy
05 juin 2023 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
– Significant investigator and patient interest drove strong recruitment of 77 patients exceeding the 60 patient target – – Topline PAVIA data anticipated in 2Q 2024 – WATERTOWN, Mass., June ...
EyePoint Pharmaceuticals to Present at the Jefferies Healthcare Conference
31 mai 2023 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16 mai 2023 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., May 16, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve...
EyePoint Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Developments
03 mai 2023 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
– Completed enrollment in the oversubscribed Phase 2 DAVIO 2 clinical trial evaluating EYP-1901 in wet age-related macular degeneration (AMD); topline data anticipated in 4Q 2023 – Enrollment...
EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023
26 avr. 2023 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of...
EyePoint Pharmaceuticals Announces Upcoming Data Presentations at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
20 mars 2023 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
- Positive neuroprotective effect of vorolanib, the active drug in EYP-1901, in a widely validated retinal detachment model demonstrates a potential new mechanism of action for the treatment of...
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Developments
02 mars 2023 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
– Phase 2 DAVIO 2 clinical trial in wet AMD on track with topline data anticipated by year-end 2023 – – Phase 2 PAVIA clinical trial in non-proliferative diabetic retinopathy (NPDR) on track with...
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
27 févr. 2023 08h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients...